Clinical Trial Update: Clinical Trial of PCV24 in Infants and Children Aged 2 Months to 5 Years [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial of the 24-valent pneumococcal conjugate vaccine PCV24 in infants and children aged 2 months to 5 years is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumococcal Infection

Drugs mentioned

• PCV24 (24-valent pneumococcal conjugate vaccine)

Snippet

Sponsor: Sinovac Life Sciences Co., Ltd. | Conditions: Pneumococcal Infectious Disease | Phase 2 | Status: RECRUITING